Strategies of assessing and quantifying radiation treatment metabolic tumor response using F18 FDG Positron Emission Tomography (PET)

Acta Oncologica

Volumn 49, Issue 7, 2010, Pages 948-955

  Fuss, Martin ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG METABOLISM; DRUG TUMOR LEVEL; GLUCOSE UTILIZATION; HUMAN; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; VOXEL BASED MORPHOMETRY;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77956581072     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.510533     Document Type: Review

References (33)

1. Kubota K. From tumor biology to clinical Pet: A review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471-486
2. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20: 379-387
3. Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 2004;45:930-932
4. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34:414-419
5. Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32:1548-1555
6. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-3844
7. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J Clin Oncol 2008;26:2155-2161
8. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8. [9]
9. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000;27:643-646
10. Janssen MH, Ollers MC, van Stiphout RG, Riedl RG, van den Bogaard J, Buijsen J, et al. Blood glucose level normalization and accurate timing improves the accuracy of PET-based treatment response predictions in rectal cancer. Radiother Oncol 2010;95:203-208
11. Torizuka T, Clavo AC, Wahl RL. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med 1997;383:382-386
12. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39:1030-1033
13. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevalua-tion of the standardized uptake value for FDG: Variations with body weight and methods for correction. Radiology 1999;213:521-525
14. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 1993;189:847.
15. Nakamoto Y, Zasadny KR, Minn H, Wahl RL. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol 2002;4:171-178
16. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995;196:167-173
17. Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40: 1771-1777
18. Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008;49:1804-1808
19. Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005;32:294-301.
20. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059-1066
21. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and sub-clinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-1782
22. Henderson MA, Hoopes DJ, Fletcher JW, Lin PF, Tann M, Yiannoutsos CT, et al. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:789-795
23. Janssen MH, Ollers MC, van Stiphout RG, Buijsen J, van den Bogaard J, de Ruysscher D, et al. Evaluation of early metabolic responses in rectal cancer during combined radio-chemotherapy or radiotherapy alone: Sequential FDG-PET-CT findings. Radiother Oncol 2010;94:151-155
24. Jingu K, Kaneta T, Nemoto K, Takeda K, Ogawa Y, Ariga H, et al. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esopha-geal cancer. Int J Clin Oncol 2010;15:184-190
25. Schwarz JK, Lin LL, Siegel BA, Miller TR, Grigsby PW. 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2008;72:1502-1507
26. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-50S.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
28. Grégoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: A new standard? J Nucl Med 2007;48S:68-77.
29. van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006; 32:245-260
30. El-Bassiouni M, Ciernik IF, Davis JB, El-Attar I, Reiner B, Burger C, et al. [18FDG] PET-CT-based intensity-modu lated radiotherapy treatment planning of head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:286-293
31. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 2007;67:720-726
32. Muijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT, et al. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol 2010 (in press).
33. Hanna GG, Carson KJ, Lynch T, McAleese J, Cosgrove VP, Eakin RL, et al. (18)F-Fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: Delineation by radiation oncologists vs. joint outlining with a PET radiologist? Int J Radiat Oncol Biol Phys 2010 (in press).